Histogenics Corp (HSGX) Shares Bought by BlackRock Inc.
BlackRock Inc. grew its position in shares of Histogenics Corp (NASDAQ:HSGX) by 72.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 54,753 shares of the biotechnology company’s stock after purchasing an additional 22,927 shares during the quarter. BlackRock Inc. owned 0.19% of Histogenics worth $137,000 as of its most recent filing with the SEC.
Separately, JPMorgan Chase & Co. bought a new stake in shares of Histogenics during the 1st quarter worth $320,000. Hedge funds and other institutional investors own 36.43% of the company’s stock.
HSGX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $3.50 price objective on shares of Histogenics in a research note on Monday, August 13th. Brookline Cap M reissued a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. Needham & Company LLC raised their price objective on Histogenics to $5.00 and gave the stock a “buy” rating in a research note on Thursday, September 6th. Zacks Investment Research lowered Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, BTIG Research lowered Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price objective for the company. in a research note on Wednesday, September 5th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $3.25.
Histogenics (NASDAQ:HSGX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05). Research analysts expect that Histogenics Corp will post -0.22 EPS for the current year.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.